Market capitalization | $288.78m |
Enterprise Value | $218.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.72 |
P/S ratio (TTM) P/S ratio | 0.95 |
P/B ratio (TTM) P/B ratio | 1.41 |
Revenue growth (TTM) Revenue growth | -10.28% |
Revenue (TTM) Revenue | $303.91m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a AngioDynamics, Inc. forecast:
3 Analysts have issued a AngioDynamics, Inc. forecast:
May '24 |
+/-
%
|
||
Revenue | 304 304 |
10%
10%
|
|
Gross Profit | 142 142 |
9%
9%
|
|
EBITDA | -6.13 -6.13 |
142%
142%
|
EBIT (Operating Income) EBIT | -34 -34 |
81%
81%
|
Net Profit | -184 -184 |
252%
252%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.
Head office | United States |
CEO | James Clemmer |
Employees | 748 |
Founded | 1988 |
Website | www.angiodynamics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.